Over time Gleason Scores have changed. Older Gleason grades are under-scored compared to today and about 20% of prostate cancer biopsies have major errors. The need for second biopsy patholoy opinions is vital.
Zytiga And Prednisone Provide Significant Benefits Beyond Survival With Newly Diagnosed Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer
The Importance of Being In Charge of Your Health Care Decision Making
Medicare Issues A “C” Code for Coverage of HIFU Treatment of Prostate Cancer In A Hospital Setting
A Better Diagnostic Marker Then PSA
Bisphosphonate Treatment for Men with Non-Metastatic Prostate Cancer Treated With ADT
The Need for Additional Research to Develop Prognostic Tools
Understanding How The Confusion Around Drug Names Develops
Do You Want To Become A Peer Reviewer for the Department of Defense Prostate Cancer Program?
Cancer ABCs Opposes The Proposed Senate Healthcare Legislation
Two Possible Clinical Trial End Points Predicting Survival and Death
The gold standard of clinical trial end points is survival. Since prostate cancer tends to move relatively slowly it can take many years for a clinical trial to be completed. We need better surrogate endpoints for survival so that trials can be completed more quickly allowing new drugs to flow to us.
